	US 12,303,471 B2
	Methods of treatment of temozolomide-resistant glioma using coenzyme Q10
Niven Rajin Narain, Cambridge, MA (US); Rangaprasad Sarangarajan, Boylston, MA (US); Vivek K. Vishnudas, Bedford, MA (US); Anne R. Diers, Wilmington, MA (US); and Stephane Gesta, Concord, MA (US)
Assigned to BPGbio, Inc., Framingham, MA (US)
Filed by BPGbio, Inc., Framingham, MA (US)
Filed on Jan. 10, 2022, as Appl. No. 17/572,092.
Application 17/572,092 is a continuation of application No. 15/353,724, filed on Nov. 16, 2016, abandoned.
Claims priority of provisional application 62/256,107, filed on Nov. 16, 2015.
Prior Publication US 2022/0202741 A1, Jun. 30, 2022
Int. Cl. A61K 31/122 (2006.01); A61K 9/00 (2006.01); A61K 31/495 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/22 (2006.01)

CPC A61K 31/122 (2013.01) [A61K 9/0019 (2013.01); A61K 31/495 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)]

21 Claims

1. A method of treating a glioma in a subject, the method comprising administering to the subject;

a) a composition comprising a Coenzyme Q10 compound; and

b) temozolomide (TMZ), thereby treating the glioma in the subject, wherein the composition comprising the Coenzyme Q10 compound is administered by injection or infusion.